This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Trending Stock Moderna, Inc. (MRNA) a Buy Now?
by Zacks Equity Research
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy
by Zacks Equity Research
Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine
Moderna (MRNA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 110.73% and 60.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More
by Kinjel Shah
Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.
Should You Buy Moderna (MRNA) Ahead of Earnings?
by Zacks Equity Research
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023.
The Zacks Analyst Blog Highlights Advanced Micro Devices, The Cigna Group, Moderna, Parker-Hannifin and Rollins
by Zacks Equity Research
Advanced Micro Devices, The Cigna Group, Moderna, Parker-Hannifin and Rollins are included in this Analyst Blog.
Top Stock Reports for AMD, Cigna & Moderna
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Advanced Micro Devices, Cigna and Moderna.
Will Pfizer (PFE) Beat Expectations This Earnings Season?
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q1.
Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $130.07, moving -0.5% from the previous trading session.
Moderna (MRNA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $142.82, marking a +0.13% move from the previous day.
Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates
by Zacks Equity Research
Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector.
FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations
by Sundeep Ganoria
To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $142.63, moving -0.93% from the previous trading session.
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence
by Zacks Equity Research
Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death.
3 Medical Stocks With Solid Growth Potential to Keep Track Of
by Indrajit Bandyopadhyay
Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.
Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSP
Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.